CLINICAL TRIALS PROFILE FOR SIMPONI ARIA
All Clinical Trials for SIMPONI ARIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01212653 ↗ | Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS) | Completed | Chinese University of Hong Kong | Phase 4 | 2010-10-01 | 1. To determine the effect of Golimumab treatment on the number and function of Endothelial Progenitor Cells (EPCs) in Ankylosing Spondylitis(AS) patients as a possible mechanism for the effect of this treatment on endothelial function. 2. To ascertain the effect of Golimumab treatment on , carotid intima-media thickness, vascular stiffness in Ankylosing Spondylitis(AS) patients as measured by pulse wave velocity (PWV) and Augmentation index (AIx). 3. To assess the clinical efficacy of Golimumab in Chinese Ankylosing Spondylitis(AS) patients according to ASAS response criteria at month 3, 6 and 12. 4. To perform cost-effectiveness and cost-utility analyses of the Golimumab in Ankylosing Spondylitis(AS) patients, using clinic-base data. |
| NCT01258777 ↗ | A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects | Completed | Centocor, Inc. | Phase 1 | 2010-10-01 | The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males. |
| NCT01288157 ↗ | A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects | Completed | Centocor, Inc. | Phase 1 | 2010-09-01 | The purpose of this study is to evaluate the pharmacokinetics of golimumab in Chinese male participants. |
| NCT01313858 ↗ | A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) | Completed | Merck Sharp & Dohme Corp. | 2010-04-01 | This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SIMPONI ARIA
Condition Name
Clinical Trial Locations for SIMPONI ARIA
Trials by Country
Clinical Trial Progress for SIMPONI ARIA
Clinical Trial Phase
Clinical Trial Sponsors for SIMPONI ARIA
Sponsor Name
